Asia Pacific Biotechnology And Pharmaceutical Services Outsourcing Market Size | Companies
The Asia Pacific biotechnology and pharmaceutical services outsourcing market size was exhibited at USD 19.18 billion in 2023 and is projected to hit around USD 35.23 billion by 2033, growing at a CAGR of 6.27% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 20.38 Billion |
| Market Size by 2033 | USD 35.23 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.27% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | End-use, Service, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | China; India; Japan; Australia; South Korea; Thailand |
| Key Companies Profiled | Dr. Reddy’s Laboratories; MSN Laboratories; Syngene International Ltd.; Aragen Life Sciences Ltd.; Bellen; Arlak Biotech Pvt. Ltd.; Gracure Pharmaceuticals Ltd.; Nvron Life Science |
The market growth can be attributed to the increasing number of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) in countries, such as China and India.
The Asia Pacific biotechnology and pharmaceutical services outsourcing market held a share of 42.4% of the global biotechnology and pharmaceutical services outsourcing market revenue in 2023. Several biotechnology and pharmaceutical companies from developed economies in North America and Europe are opting to outsource various business functions, such as manufacturing, research & development, distribution, drug development, and clinical trials, to contract organizations operating in the region. In recent decades, countries, such as China, India, and Japan, have experienced advancements in industrial infrastructure, availability of technology, and accessibility to resources.
This has resulted in the establishment of outsourcing industry participants who have been running businesses successfully with continuous enhancements. It has also resulted in the availability of experienced professionals, accessibility to innovative technologies, and lower costs of labor and drug development & production. A growing number of contract development and manufacturing organizations (CDMOs) is primarily driving the growth of this market in Asia Pacific. Some of the CDMOs operating in the region are Piramal Pharma Solutions, Syngene International Limited, Sai Life Sciences, and others.
Based on the end-use, the pharmaceutical companies segment held the highest revenue share of 58.11% in 2023. China has been one of the most preferred locations for many pharmaceutical businesses, in terms of outsourcing research and manufacturing functions. In recent years, India has also been emerging as an alternative for similar services. Positive changes in industrial infrastructure, supportive government initiatives, increasing availability of skilled professionals, and accessibility to advancing technology have attracted many pharmaceutical companies from the U.S., Europe, and other parts of the world.
The biotech companies segment is expected to experience a CAGR of 6.66% from 2024 to 2033. India has been one of the leading manufacturers of generic drugs and exports large amounts of generics to countries, such as the U.S. and others. In recent years, factors, such as lower costs for manufacturing, clinical trials, distribution, world-class facilities provided by CDMOs in the region, the presence of technical expertise, and skilled professionals have driven the growth of this segment.
The consulting services segment dominated the regional market and held a revenue of 23.19% in 2023. Pharmaceutical industry consulting services include clinical development, regulatory affairs, strategic planning, business development, quality management, and more. In addition, aspects, such as R&D, resource management, digital transformation, Environmental, Social, and Governance (ESG), risks & regulations, sales & marketing, and medical technology are also part of consulting services provided by organizations to leading companies in the biotechnology and pharmaceutical industry.
The training & education segment is expected to witness a CAGR of 4.11% from 2024 to 2033. Outsourcing functions, such as employee skill development, learning, and development has been one of the prominent trends as many pharmaceutical companies have been focusing on their core competencies and strengths. Cost-effective outsourcing services offered by organizations in the market, emerging providers of e-learning solutions, and talented instructors have been fueling the segment's growth.
China Biotechnology And Pharmaceutical Services Outsourcing Market Trends
China biotechnology and pharmaceutical services outsourcing market dominated the regional industry and accounted for a share of 29.3% in 2023. This is primarily due to factors, such as lower labor costs, reputation as one of the most preferred alternatives for outsourcing services, and availability of infrastructure. In addition, favorable government policies that have been welcoming pharmaceutical companies to outsource their business functions such as clinical trials and drug development to contractors in China have been driving the market.
India Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in India is expected to experience a significant CAGR of 6.72% from 2024 to 2033. This can be attributed to advancements in industrial infra, availability of world-class facilities, presence of skilled professionals, and lower costs associated with procurement of materials and other business area
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific biotechnology and pharmaceutical services outsourcing market
End-use
Service
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of primary research
1.6. Market Formulation & Validation
1.7. Region-wise Market Calculation
1.7.1. Region-Wise Market: Base Estimates
1.7.2. Global Market: CAGR Calculation
1.7.3. Region Based Segment Share Calculation
1.8. Model Details
1.8.1. Commodity flow analysis (Model 1)
1.8.1.1. Approach 1: Commodity flow approach
1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
1.8.3. QFD Model Sizing & Forecasting (Model 3)
1.8.4. Bottom-up Approach (Model 4)
1.9. Research Scope and Assumptions
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. List of Abbreviations
1.13. Objectives
1.13.1. Objective 1
1.13.2. Objective 2
1.13.3. Objective 3
1.13.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Outsourcing of R&D Activities
3.2.1.2. Changing Regulatory Landscape
3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
3.2.1.5. Increasing Mergers and Collaborations
3.2.2. Market Restraint Analysis
3.2.2.1. Monitoring Issues and Lack of Standardization\
3.2.2.2. Loss of Control
3.2.2.3. Data Security Issues
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Clinical Trials Volume Analysis
3.6. R&D Investment Analysis
3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2021 to 2033
4.4. Consulting
4.4.1. Consulting Market Revenue Estimates and Forecasts, 2021 - 2033
4.4.2. Regulatory Consulting
4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2021 - 2033
4.4.3. Clinical Development Consulting
4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2021 - 2033
4.4.4. Strategic Planning & Business Development Consulting
4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2021 - 2033
4.4.5. Quality Management Systems Consulting
4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2021 - 2033
4.4.6. Others
4.4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033
4.5. Regulatory Affairs
4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.2. Legal Representation
4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.3. Regulatory Writing & Publishing
4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.4. Product Registration & Clinical Trial Applications
4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.5. Regulatory Submissions
4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.6. Regulatory Operations
4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2021 - 2033
4.5.7. Others
4.5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033
4.6. Product Design & Development
4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2021 - 2033
4.7. Auditing and Assessment
4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2021 - 2033
4.8. Product Maintenance
4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2021 - 2033
4.9. Training & Education
4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2021 - 2033
4.10. Others
4.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033
Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2021 to 2033
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2021 - 2033
5.5. Biotech Companies
5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2021 - 2033
Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis, by Service, by End-Use
6.1. Regional Dashboard
6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
6.3. North America
6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.3.2. U.S.
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4. Europe
6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5. Asia Pacific
6.5.1. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.6. Latin America
6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.6.3. Mexico
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.6.4. Argentina
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.7. Middle East & Africa
6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.7.4. UAE
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2023
7.3. Service Heat Map Analysis
7.4. Company Profiles
7.4.1. Parexel International Corporation
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. The Quantic Group
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. IQVIA
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Lachman Consultant Services, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. GMP Pharmaceuticals Pty Ltd.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Concept Heidelberg GmbH
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. LabCorp
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Charles River Laboratories
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. ICON plc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Service Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Syneos Health
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Service Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Lonza
7.4.11.1. Company Overview
7.4.11.2. Financial Performance
7.4.11.3. Service Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. Catalent Inc.
7.4.12.1. Company Overview
7.4.12.2. Financial Performance
7.4.12.3. Service Benchmarking
7.4.12.4. Strategic Initiatives
7.4.13. Samsung Biologics
7.4.13.1. Company Overview
7.4.13.2. Financial Performance
7.4.13.3. Service Benchmarking
7.4.13.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers